专利号:US-2023271983-A1 优先权日:2020-07-29 标题 :Functionalized isonitriles and products, preparation and uses thereof 发明人:SOTELO PÉREZ EDDY; AZUAJE GUERRERO JHONNY ALBERTO; MAJELLARO MARIA 权利人:UNIV SANTIAGO COMPOSTELA 摘要:The present invention relates to functionalized isonitrile compounds, formed by means of multicomponent environmentally friendly reactions, suitable for coupling to functional molecules such as biomolecules, APIs, chromophore and fluorophore molecules. The invention also relates to conjugates between said isonitrile compounds and functional molecules, which are useful in the synthesis of pharmaceutic drugs or tools, fluorescent molecules and labels, polymeric smart materials. The invention furthermore provides a kit for the in-vitro preparation of the functionalized isontrile compounds and conjugates. The invention also contemplates the medical use of said compounds and conjugates.
专利号:US-2008269233-A1 优先权日:2005-08-04 标 题:Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds 发明人:ANDREWS MARK DAVID; BROWN ALAN DANIEL; SEBASTIEN DAVID; LANSDELL MARK IAN 权利人:ANDREWS MARK DAVID; BROWN ALAN DANIEL; SEBASTIEN DAVID; LANSDELL MARK IAN 摘要:The present invention relates to a class of compounds of general formula (I) n n n n n n n n n n and the salts, hydrates, solvates, polymorphs and prodrugs wherein n, R 6 , R 7 and R 10 are as defined herein and especially to MCR4 agonist compounds of formula (I), to their use in medicine, particularly in the treatment of sexual dysfunction and obesity, to intermediates useful in their synthesis and to compositions containing them.
专利号:US-8138188-B2 优先权日:2006-02-23 标题 :Melanocortin type 4 receptor agonist piperidinoylpyrrolidines 发明人:ANDREWS MARK DAVID; BROWN ALAN DANIEL; LANSDELL MARK IAN; SUMMERHILL NICHOLAS WILLIAM 权利人:ANDREWS MARK DAVID; BROWN ALAN DANIEL; LANSDELL MARK IAN; SUMMERHILL NICHOLAS WILLIAM; PFIZER 摘要:The present invention relates to a class of melanocortin MCR4 agonists of general formula (I) n nwherein the variables and substituents are as defined herein and especially to selective MCR4 agonist compounds, to their use in medicine, particularly in the treatment of sexual dysfunction and obesity, to intermediates useful in their synthesis and to compositions containing them.
专利号:CN-114085197-B 优先权日:2021-12-01 标题:4-(3-Trifluoromethylphenyl)-1-piperazine-ethanol, flibanserin intermediates, and synthesis methods of flibanserin
1: Simon JA, Clayton AH, Parish SJ, Apfel SC, Millheiser L. Effects of Alcohol Administered With Flibanserin in Healthy Premenopausal Women: A Randomized, Double-Blind, Single-Dose Crossover Study. J Sex Med. 2019 Nov 14. pii: S1743-6095(19)31459-6. doi: 10.1016/j.jsxm.2019.10.004. [Epub ahead of print] Available from http://www.ncbi.nlm.nih.gov/books/NBK548074/ Available from http://www.ncbi.nlm.nih.gov/books/NBK546788/ doi: 10.1016/j.jsxm.2019.08.006. Epub 2019 Sep 12. doi: 10.1016/j.esxm.2019.08.003. Epub 2019 Sep 10. doi: 10.1016/j.saa.2019.117491. [Epub ahead of print] doi: 10.1186/s13065-019-0620-9. eCollection 2019 Dec. 8: Simon JA, Kingsberg SA, Goldstein I, Kim NN, Hakim B, Millheiser L. Weight Loss in Women Taking Flibanserin for Hypoactive Sexual Desire Disorder (HSDD): Insights Into Potential Mechanisms. Sex Med Rev. 2019 Oct;7(4):575-586. doi: 10.1016/j.sxmr.2019.04.003. Epub 2019 Jun 10. Review. doi: 10.1002/bmc.4545. Epub 2019 May 6. doi: 10.1016/j.sxmr.2018.12.003. Epub 2019 Feb 22. Review. doi: 10.1089/jwh.2018.7516. Epub 2019 Feb 1. doi: 10.4103/ipj.ipj_20_16. 13: Shingare RD, Kulkarni AS, Sutar RL, Reddy DS. Route to Benzimidazol-2-ones via Decarbonylative Ring Contraction of Quinoxalinediones: Application to the Synthesis of Flibanserin, A Drug for Treating Hypoactive Sexual Desire Disorder in Women and Marine Natural Product Hunanamycin Analogue. ACS Omega. 2017 Aug 31;2(8):5137-5141. doi: 10.1021/acsomega.7b00819. Epub 2017 Aug 29.
合成参考文献
摘要:NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm setid=3819daf3-e935-2c53-c527-e1d57922f394